---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-066700"
form_type: "8-K"
ticker: "HOOK"
cik: "0001760542"
company_name: "HOOKIPA Pharma Inc."
filed_at: "2023-05-31T23:59:59+00:00"
generated_at: "2026-06-14T10:40:18.151327+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# HOOKIPA Phase 2 HB-200 data: 43% ORR with pembrolizumab vs 19% historical; pivotal trial planned for 2024

## Summary
- HB-200 + pembrolizumab showed 43% objective response rate (6/14 patients) in 1st-line HPV16+ head/neck cancer, doubling pembrolizumab alone.
- Median overall survival of 14.2 months in heavily pre-treated monotherapy cohort (n=11, median follow-up 12.8 months).
- Safety: 7% serious adverse events related to HB-200; 2% discontinuation rate across 132 patients.
- Company preparing to start pivotal trial of HB-200 + pembrolizumab in 1st-line setting in 2024.
- HB-200 induced rapid, sustained T-cell responses for at least 8 months associated with clinical benefit.

## SEC filing metadata
- accession: 0001104659-23-066700
- form_type: 8-K
- ticker: HOOK
- cik: 0001760542
- company_name: HOOKIPA Pharma Inc.
- filed_at: 2023-05-31T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1760542/000110465923066700/0001104659-23-066700-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1760542/000110465923066700/tm2317399d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-066700
- JSON: https://secwatch.observer/filing/0001104659-23-066700.json
- Plain text: https://secwatch.observer/filing/0001104659-23-066700.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.